The plasma protease C1-inhibitor treatment market has been gaining significant traction over the past decade, owing to the growing prevalence of hereditary angioedema (HAE) across the globe. C1-inhibitor treatments are plasma derived products used for the treatment of acute attacks and prophylaxis of HAE. They inhibit complement component 1 esterase and are effective for managing HAE attacks as well as reducing their frequency and severity. These therapies offer advantages such as quick onset of action, high treatment efficacy rates, and extended protection for preventing new attacks. Growing awareness about the availability of preventive treatment options and increasing diagnosis rates are fueling the demand for C1-inhibitor therapies among HAE patients worldwide.

The Global plasma protease C1-inhibitor Treatment Market Demand is estimated to be valued at US$ 6257.99 Bn in 2024 and is expected to exhibit a CAGR of 6.7% over the forecast period 2024 to 2030.

Key Takeaways

Key players operating in the plasma protease C1-inhibitor treatment market are R&D, Koninklijke Philips N.V., Panasonic Corporation, and Procter & Gamble. R&D has leading brands such as Cinryze and Haegarda used for HAE treatment. Koninklijke Philips N.V is a major medical devices manufacturer offering diagnostic products for plasma protease C1-inhibitor treatment monitoring.

The growing prevalence of hereditary angioedema globally is driving the demand for plasma protease C1-inhibitor treatments. As per research, HAE affects approximately 1 in 10,000 to 1 in 50,000 people worldwide. Cases are being increasingly reported across populations that were previously considered low-risk.

Increasing accessibility of C1-inhibitor therapies in international markets is boosting the global expansion of the plasma protease C1-inhibitor treatment market. Various companies are gaining regulatory approvals and marketing authorizations to launch their products in new countries. This is enabling more HAE patients to access preventive medications and reducing disease and economic burden.

Market Drivers

The risingawareness about HAE and availability of effective prophylactic treatment options are some of the major factors propelling the growth of plasma protease C1-inhibitor treatment market. Earlier, HAE was considered a rare condition with limited medical management options. However, extensive research has enhanced understanding of the pathophysiology of the disease. This is encouraging more patients to seek diagnosis and long-term prevention of attacks through C1-inhibitor replacement therapies. Furthermore, companies continuously investing in the development of improved formulations with superior clinical profiles will augment the demand.

The current geopolitical conflicts and economic uncertainties have negatively impacted the plasma protease C1-inhibitor treatment market globally. The ongoing Russia-Ukraine war has exacerbated challenges in the supply chain and logistics network. It has led to increased prices of raw materials and disrupted supplies of essential medical devices and equipment required for plasma protease C1-inhibitor treatment procedures. Moreover, economic sanctions and export restrictions on Russia by western countries are hampering international trade and commerce. This is restricting the market from achieving its full potential in the European region.

The market is also facing headwinds due to rising political tensions between the US and China. Any further economic decoupling between these two countries would be detrimental. Additionally, the lingering effects of the COVID-19 pandemic like reduced funding for non-COVID healthcare, shifting focus of healthcare systems, and changed investment patterns continue posing challenges. To overcome these obstacles, the companies operating in this market need to diversify their supply chain network, look for alternative supplier options, and explore opportunities in other fast growing regions like Asia Pacific and Latin America. Significant investments are required in digitalization and development of innovative therapeutics to strengthen their market position amid geopolitical instability.

The North American region currently accounts for the largest share of the global plasma protease C1-inhibitor treatment market in terms of value. This is attributed to factors such as rising prevalence of hereditary angioedema in the US and Canada, growing awareness about available treatment options, strong healthcare infrastructure, and high adoption of advanced therapies. Moreover, presence of leading market players, favorable reimbursement policies, and large healthcare expenditure contribute to the high market concentration in North America.

Europe is the second most lucrative region for plasma protease C1-inhibitor treatment providers. Countries like Germany, France, UK, Italy, and Spain have seen increased diagnosis and demand for plasma protease C1-inhibitor drugs due to presence of supportive patient associations. Additionally, the region has experienced approval and launch of various novel therapies in recent years thus attracting more patients undergoing treatment. Asia Pacific is emerging as a high potential market owing to rapidly developing healthcare systems, increasing medical tourism, and rising disposable incomes in nations like China, India, Japan, and South Korea.

Get more insights on this topic: Plasma Protease C1-inhibitor Treatment Market